Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Mantle-Cell

Explore clinical trials studying Lymphoma, Mantle-Cell. Study availability and eligibility vary by location and protocol.

889 public trials 111 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Mantle-Cell trial results

Completed

Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL

NCT03567876

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • A.O. SS. Antonio e Biagio e Cesare Arrigo, SC Ematologia Alessandria, Italy
  • Università Politecnica delle Marche, Clinica di Ematologia Ancona, Italy
  • Centro Riferimento Oncologico, S.O.C. Oncologia Medica A Aviano, Italy
  • IRCCS Istituto Tumori Giovanni Paolo II, UOC Ematologia Bari, Italy
View all 35 locations
View Trial Details
Completed

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

NCT02568553

Conditions
Burkitt Lymphoma, Chronic Disease, DNA Virus Infections, +53 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • Los Angeles General Medical Center Los Angeles, California, United States
View all 24 locations
View Trial Details
Completed

Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

NCT04172246

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +28 more
Locations
  • Nagoya University Hospital Nagoya, Aichi-ken, Japan
  • Toyohashi Municipal Hospital Toyohashishi, Aichi-ken, Japan
  • Chiba Cancer Center Chiba, Japan
  • Matsuyama Red Cross Hospital Matsuyama, Ehime, Japan
View all 15 locations
View Trial Details
Completed

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

NCT04880434

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Stanford University Palo Alto, California, United States
  • University California Los Angeles (UCLA) Santa Monica, California, United States
  • Sarah Cannon- Denver Denver, Colorado, United States
View all 40 locations
View Trial Details
Completed

A Disease Registry of Patients With Mantle Cell Lymphoma

NCT03816683

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Research Site Montgomery, Alabama, United States
  • Research Site Clovis, California, United States
  • Research Site Boulder, Colorado, United States
  • Research Site Jacksonville, Florida, United States
View all 32 locations
View Trial Details
Completed

Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

NCT00310037

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States
  • Illinois CancerCare - Bloomington Bloomington, Illinois, United States
  • St. Joseph Medical Center Bloomington, Illinois, United States
  • Graham Hospital Canton, Illinois, United States
View all 48 locations
View Trial Details
Completed

A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

NCT05564052

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • Santa Casa de Misericordia de Belo Horizonte Belo Horizonte, Brazil
  • Sociedade Beneficente de Senhoras - Hospital Sirio Libanes HSL Unidade Brasilia Brasília, Brazil
  • Ynova Pesquisa Clinica Florianópolis, Brazil
  • Liga Norte Riograndense Contra O Cancer Natal, Brazil
View all 66 locations
View Trial Details

Related conditions